SCHEMBL2177947

SCHEMBL2177947

CCCCOc1ccc(C(=O)Nc2ccc(-c3ccc4c(c3)C(=O)N(C(C(=O)O)C(C)C)C4)c(C)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 5/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
TP53 P04637 4/20 0.44
KDM4E B2RXH2 2/20 0.43
RAB9A P51151 2/20 0.43
NR1H4 Q96RI1 2/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ITGB3 P05106 2/20 0.42
ITGA2B P08514 2/20 0.42
ITGA2 P17301 2/20 0.42
LMNA P02545 3/20 0.42
ALDH1A1 P00352 2/20 0.41
DGAT1 O75907 1/20 0.41
MCHR1 Q99705 2/20 0.41
HIF1A Q16665 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2181553 1.00 MEN1 (0.47) MEN1KMT2AMAPTSMN1; SMN2TP53
SCHEMBL2179853 0.92 MEN1 (0.47) MEN1KMT2AMAPTSMN1; SMN2TP53
SCHEMBL2180348 0.92 MEN1 (0.47) MEN1KMT2AMAPTSMN1; SMN2TP53
SCHEMBL2177126 0.92 MEN1 (0.47) MEN1KMT2AMAPTSMN1; SMN2TP53
SCHEMBL2180778 0.92 MEN1 (0.47) MEN1KMT2AMAPTSMN1; SMN2TP53
SCHEMBL13719368 0.91 MAPT (0.48) MEN1KMT2AMAPTSMN1; SMN2TP53
SCHEMBL2179355 0.91 MAPT (0.48) MEN1KMT2AMAPTSMN1; SMN2TP53
SCHEMBL2177053 0.89 MEN1 (0.45) MEN1KMT2AMAPTSMN1; SMN2TP53
SCHEMBL13718578 0.89 MEN1 (0.45) MEN1KMT2AMAPTSMN1; SMN2TP53
SCHEMBL2176949 0.89 RARB (0.44) MAPTSMN1; SMN2TP53KDM4EITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT MEN1 3071/4885KMT2A 1705/4885MAPT 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.